Tonix Pharmaceuticals to Showcase Innovations at 2025 BIO International Convention

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) is gearing up for a significant presentation at the 2025 BIO International Convention in Boston, where CEO Seth Lederman, M.D., will share insights into the company's pioneering work in biopharmaceuticals. Scheduled for June 16 at 5:00 p.m. in Room 153B of the Boston Convention & Exhibition Center, this presentation underscores Tonix's role in transforming pain management therapies and tackling public health issues.

The company's focus on submitting a New Drug Application (NDA) for TNX-102 SL, a promising treatment for fibromyalgia, marks a critical step forward in addressing a condition that affects millions worldwide. With Fast Track designation from the FDA, TNX-102 SL represents a beacon of hope for patients suffering from fibromyalgia, a chronic disorder characterized by widespread musculoskeletal pain. The successful completion of two statistically significant phase 3 studies for TNX-102 SL highlights its potential as a well-tolerated and effective treatment option.

Beyond fibromyalgia, Tonix Pharmaceuticals is making strides in developing treatments for acute stress reaction and infectious diseases, including a $34 million contract with the U.S. Department of Defense to develop TNX-4200. This small molecule broad-spectrum antiviral agent aims to protect military personnel from biological threats, showcasing Tonix's commitment to national and global health security.

Tonix's state-of-the-art facilities in Maryland, capable of Good Manufacturing Practice (GMP), further demonstrate the company's readiness to respond to health emergencies and its dedication to advancing CNS disorders, immunology, rare diseases, and infectious disease treatments. With a robust development portfolio and commercial products like Zembrace SymTouch and Tosymra for migraine treatment, Tonix Pharmaceuticals is at the forefront of biopharmaceutical innovation.

The presentation at the 2025 BIO International Convention is not just a platform for Tonix to share its achievements but also an opportunity to highlight the importance of innovative therapies in improving patient outcomes and addressing unmet medical needs. As the biopharmaceutical industry continues to evolve, Tonix's contributions could have far-reaching implications for healthcare professionals, patients, and the broader medical community.